Cargando…

Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States

IMPORTANCE: Because of historical associations between vaccines and Guillain-Barré syndrome (GBS), the condition was a prespecified adverse event of special interest for COVID-19 vaccine monitoring. OBJECTIVE: To evaluate GBS reports to the Vaccine Adverse Event Reporting System (VAERS) and compare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abara, Winston E., Gee, Julianne, Marquez, Paige, Woo, Jared, Myers, Tanya R., DeSantis, Allison, Baumblatt, Jane A. G., Woo, Emily Jane, Thompson, Deborah, Nair, Narayan, Su, John R., Shimabukuro, Tom T., Shay, David K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892957/ https://www.ncbi.nlm.nih.gov/pubmed/36723942 http://dx.doi.org/10.1001/jamanetworkopen.2022.53845

Ejemplares similares

Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status — United States, January 12, 2022–March 28, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021–February 2022
por: Woo, Emily Jane, et al.
Publicado: (2023)

Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults
por: Tompkins, Lindsay K., et al.
Publicado: (2022)

Notes from the Field: Safety Monitoring of Novavax COVID-19 Vaccine Among Persons Aged ≥12 Years — United States, July 13, 2022–March 13, 2023
por: Romanson, Brittney, et al.
Publicado: (2023)

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe
por: Rosenblum, Hannah G, et al.
Publicado: (2022)

COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5–11 Years — United States, October 12–January 1, 2023
por: Hause, Anne M., et al.
Publicado: (2023)

Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system
por: Chapin-Bardales, Johanna, et al.
Publicado: (2021)

COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months–5 Years — United States, June 18, 2022–August 21, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021
por: Shay, David K., et al.
Publicado: (2021)

Hyperreflexic Guillain-Barré syndrome
por: Baheti, Neeraj N., et al.
Publicado: (2010)

Guillain–Barré syndrome
por: Mirian, Ario, et al.
Publicado: (2021)

Guillain-Barre syndrome after lumbar epidural block
por: Yun, Myo Seop, et al.
Publicado: (2012)

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)
por: Welsh, Kerry J., et al.
Publicado: (2021)

Autoantibody screening in Guillain–Barré syndrome
por: Lleixà, Cinta, et al.
Publicado: (2021)

An Update in Guillain-Barré Syndrome
por: Winer, J. B.
Publicado: (2014)

Guillain–Barré syndrome mimics
por: Tham, Sai Leong, et al.
Publicado: (2018)

Syndrome de Guillain–Barré
por: Mirian, Ario, et al.
Publicado: (2021)

Guillain-Barré syndrome in times of pandemics
por: Leonhard, Sonja E, et al.
Publicado: (2020)

First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021
por: Gee, Julianne, et al.
Publicado: (2021)

Guillain-Barré syndrome following acute viral hepatitis A
por: Menon, Deepak, et al.
Publicado: (2014)

Vision Loss in Guillain-Barre Syndrome: Is it a Complication of Guillain-Barre Syndrome or Just a Coincidence?
por: Ramakrishnan, Sri, et al.
Publicado: (2016)

Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020–January, 2022: an observational cohort study
por: Wong, Karen K, et al.
Publicado: (2022)

Clinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in Korea
por: Park, Yong-Shik, et al.
Publicado: (2017)

Sídrome de Guillain-Barré : aspectos terapéuticos
por: Abad Alfonso, Fernando
Publicado: (1998)

Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink
por: Hanson, Kayla E., et al.
Publicado: (2022)

Treatment guidelines for Guillain–Barré Syndrome
por: Meena, A. K., et al.
Publicado: (2011)

Atypical Guillain-Barré in the Emergency Department
por: Sheridan, Josh M., et al.
Publicado: (2010)

Brucellosis, Presenting with Guillain-Barré Syndrome
por: Babamahmoodi, Farhang, et al.
Publicado: (2011)

Guillain-Barre syndrome and mood disorders
por: Neroutsos, Evangelos, et al.
Publicado: (2010)

Syringomyelia Coexisting With Guillain-Barre Syndrome
por: Kim, Hee-Sang, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jf6b989pu1gn4o13srf7fkjree